The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications
Authors:
- Eleni PapamattheouEleni Papamattheou
- Alkistis PapatheodoridiAlkistis Papatheodoridi
- Ioannis KatsarosIoannis Katsaros
- Garyfalia BletsaGBGaryfalia Bletsa
- Afroditi NonniANAfroditi Nonni
- Constantine DimitrakakisCDConstantine Dimitrakakis
- Dimitrios HaidopoulosDHDimitrios Haidopoulos
- Angeliki AndrikopoulouAAAngeliki Andrikopoulou
- Areti PapakostaAPAreti Papakosta
- Spyridon MarinopoulosSpyridon Marinopoulos
- Aris GiannosAGAris Giannos
- Sofia KouraSKSofia Koura
Open Access
- 18 December 2025
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (12) , 1060
Abstract
Background/objectives: Metaplastic breast carcinoma (MpBC) is a rare, poorly differentiated breast cancer defined by the presence of ductal carcinoma along with areas of matrix-producing, spindle-cell, sarcomatous, or squamous differentiation. It does not express hormone receptors and has a poor overall prognosis. The Hippo molecular pathway was recently related to cancer progression and adjuvant therapy resistance. The objective of this study was to evaluate the expression of Hippo pathway transducers, YAP/TAZ, CCND1, and CTGF, in MpBC and their relation to the clinicopathological characteristics of the disease. Methods: Specimens from patients with MpBC treated at our department from 2003 to 2021 were analyzed utilizing immunohistochemistry and real-time PCR. Results: Forty-four female patients (62.6 ± 14.7 years old) met inclusion criteria and were included in this study. Strong nuclear YAP/TAZ expression was found in 61.4% of patients, while the expressions of CCND1 and CTGF were 3.9% and 12.5%, respectively. Patients presenting at an advanced stage had a statistically worse prognosis compared to the ones diagnosed with stage IA disease. Adjuvant chemotherapy was associated with better overall survival, while disease recurrence was significantly associated with a worse prognosis. Conclusions: Advanced stage at diagnosis and disease recurrence were significantly associated with worse prognosis in MpBC. However, adjuvant chemotherapy significantly led to better overall survival. The Hippo pathway is frequently deregulated (nuclear YAP/TAZ in 61.4% of patients), suggesting it is a compelling novel therapeutic target for this aggressive disease.Keywords
This publication has 52 references indexed in Scilit:
- Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survivalBreast Cancer Research and Treatment, 2023
- Unique clinicopathological characteristic and survival rate of metaplastic breast cancer;a special subtype of breast cancer a 5 year cohort study in single referral centre in North BorneoAnnals of Medicine & Surgery, 2022
- Histological subtypes in triple negative breast cancer are associated with specific information on survivalAnnals of Diagnostic Pathology, 2020
- Comparison of outcomes between metaplastic and triple-negative breast cancer patientsThe Breast, 2020
- Prognosis in different subtypes of metaplastic breast cancer: a population-based analysisBreast Cancer Research and Treatment, 2018
- Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of LiteratureClinical Breast Cancer, 2017
- A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysisThe Breast, 2017
- Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single InstitutionClinical Breast Cancer, 2017
- Hippo pathway and breast cancer stem cellsCritical Reviews in Oncology/Hematology, 2016
- The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer CellsCell, 2011